Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which ...

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent ...

Growing up in rural Indiana, I had more animal friends than human ones. I raised ducks and geese, and enjoyed my time ...

Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ...

The story of the ozone layer is a powerful reminder of both the damage humanity can cause and the positive change we can achieve through global cooperation I ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

A NEW vaccine could cure up to half of all pancreatic cancer cases and may one day wipe out the disease entirely, scientists say. Pancreatic cancer is the deadliest cancer in the world. Some ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients – – Promising clinical activity and deep responses observed ...

A state-of-the-art Japanese warship has arrived in Australia as part of a high-stakes campaign to secure a $6.5 billion ...